Sapience lucicebtide GBM ASCO, Leerink/RBC TRIUMPH-1 weekend commentary, Corbus CRB-701 Nectin-4, Anglia Ruskin 90K-patient GLP-1 CV meta-analysis, EASL preview.
Read digest →Wegovy pill EU CHMP positive opinion, retatrutide TRIUMPH-1 analyst dysesthesia signal, Bicycle Duravelo-2 Phase 2 65% ORR, Hims $350M convertible, BriaCell 16.6mo OS.
Read digest →Retatrutide TRIUMPH-1 Phase 3 hits 28.3% weight loss + 30.3% extension, ASCO 2026 abstracts release, Regeneron-Parabilis $2.325B Helicon deal, AMAZE-12 amycretin Phase 3.
Read digest →Novo Nordisk pre-EASL ESSENCE liver safety, Parabilis IPO for zolucatetide, 20n Bio cyclic peptide AI, 5W AI citation index, CAMPER anti-MRSA peptide.
Read digest →Ozari Health telehealth $86/mo, Avacta AVA6103 FOCUS-01 Phase 1, MetaVia DA-1726 ADA, PCAC Feb 2027, TerminaTOR mTORC1, chiral peptide-drug conjugates.
Read digest →Novo international Wegovy pill expansion as US scripts cross 2M, BriaCell Bria-OVA+ ovarian pipeline, Tsinghua NK2R AI competition, Aivocode CAQK, Fibulin-4.
Read digest →Wegovy pill scripts decline for first time, Foundayo Week 5 +40%, Lilly analyst targets, Nature Biotech TCR PRP paper, retatrutide TRIUMPH timing, ASCO 2026.
Read digest →Foundayo Week 5 IQVIA 10,248 (+40% w/w), Hims 125K Wegovy shipments, daraxonrasib NEJM PDAC, FDA AI inspection pilot, peptide cancer vaccine reviews.
Read digest →ECO 2026 closes: SURMOUNT-MAINTAIN Lancet 7x maintenance odds, medRxiv $28-140/year generic semaglutide cost, Crinetics CAREFNDR + Cushing's, HIMS post-Q1.
Read digest →ECO Day 3: EASO 2026 framework first-line tirzepatide/semaglutide, CagriSema CV risk, RESETTLE young adults, Mazdutide GLORY-2 18.55%, JPM/Canaccord Hims.
Read digest →ECO Day 2: Lilly MAINTAIN dual publication, Viking VK2735 oral 12.2%, Wegovy Pill OASIS 4 21.6% early responders, ORION Wegovy vs Foundayo ITC, PepGen DM1.
Read digest →ECO 2026 opens: Wegovy 7.2 mg 28% early responders, CagriSema body composition, Foundayo UAE, Tonix Q1, Entera EB613, Oncopeptides Pepaxti EMA.
Read digest →Hims Q1 $608M, MBX once-monthly + STEADI PBH proof-of-concept, Viking VK2735 + Ascletis multi-program ECO, Padova STEP 65+ semaglutide 15.4%, LUNA18 TIDES.
Read digest →Lilly $4.5B Lebanon Indiana investment, Amylyx avexitide expanded access, Nature brain reward circuit paper, Health Canada 2nd generic semaglutide, ASC30 ECO.
Read digest →Foundayo Week 4 IQVIA, Merck enlicitide biocatalytic Science paper, Rhythm Q1 IMCIVREE $60.1M + EMANATE miss, Vertex VX-670 DM1, PolyPeptide credit.
Read digest →Crinetics Q1 Palsonify $10.3M, Zealand Q1 + $700M petrelintide milestone, AstraZeneca eleglipron Phase 2b wins, Entrada DMD positive topline, Foley legal memo.
Read digest →Nature TransCODE peptideins paper, Novo Q1 sub-detail (Wegovy 65% new-Rx, CagriSema co-formulation cut), Jefferies pushback, Lisata-Kuva amendment, Lilly quintuple agonist.
Read digest →Novo Q1 prints Wegovy pill at $354M (2× consensus), tightens guidance; Barclays + Cantor + BofA hike LLY targets; BMC DualPep-ALO hair peptide; ITM-11 PDUFA August 28.
Read digest →